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Classically, the diagnosis of diabetes has been made us-
ing the fasting plasma glucose, random plasma glucose, 
or a 2-hr 75-g oral glucose tolerance test. There are many 
problems with the definition of diabetes based on blood 
glucose levels, such as the high intra-individual biological 
variability, variability in the collection and storage meth-
ods, and difficulty in ensuring a fasting state before mea-
suring the blood glucose [1].
Recently, the hemoglobin A1c (HbA1c) assay has also been 
recommended for the diagnosis of diabetes. The HbA1c 
concentration is a good indicator of glycemic control over 
the previous 8-12 weeks; the time period is dictated by 
the 120-day lifespan of erythrocytes. HbA1c is used as the 
standard biomarker for the adequacy of glycemic manage-
ment since it correlates well with both microvascular and, 
to a lesser extent, macrovascular complications based on a 
large epidemiological study [2,3]. In the past, expert com-
mittees have rejected the proposed use of HbA1c for the 
diagnosis of diabetes mainly because of the lack of assay 
standardization. However, HbA1c assays are now highly 
standardized, and an international expert committee rec-
ommended the use of the HbA1c test to diagnose diabetes, 
with a threshold of ≥ 6.5%, in 2009 [4]. The American 
Diabetes Association (ADA) affirmed this decision in 
2010. The diagnostic test should be performed using a 
method that is certified by the National Glycohemoglobin 
Standardization Program (NGSP) and standardized or 
traceable to the Diabetes Control and Complications Trial 
reference assay [5]. An HbA1c cut-off of ≥ 6.5% is associ-
ated with an increase in the prevalence of moderate reti-
nopathy [6].
A few attempts to verify the validity of glycated hemo-
globin in diagnosing type 2 diabetes mellitus in different 
ethnic populations have been published [7]. Since many 
studies have found that ethnicity influences the HbA1c level 
[8], it is necessary to confirm the utility of HbA1c in dif-
ferent races. Recently, Yu et al. [9] investigated the valid-
ity of glycated hemoglobin in diagnosing type 2 diabetes 
mellitus in 497 Chinese subjects, and checked the fasting 
plasma glucose, oral glucose tolerance test (OGTT), and 
HbA1c. In their study, an HbA1c level of 6.5% had a sensitiv-
ity of 62.7% and a specificity of 93.5% as a diagnostic tool. 
They concluded that the optimal cut-off point of HbA1c was 
6.3% with a sensitivity of 79.6% and specificity of 82.2%. 
HbA1c ≥ 6.5% has reasonably good specificity for diagnos-
ing diabetes in Chinese, in concordance with the ADA 
recommendation [9]. These results, in terms of Asians, are 
meaningful. Yun et al. [10] also reported on the difference 
between the HbA1c assay and fasting plasma glucose level 
for making the diagnosis of diabetes in Korean adults; the 
kappa index of agreement between the fasting plasma glu-
cose level and HbA1c was 0.50.
Since HbA1c is associated with the risk of diabetes, 
HbA1c is superior to the glucose level for assessing chronic 
complications of diabetes and a study of Koreans found 
agreement between glycosylated hemoglobin and fasting 
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plasma glucose [10]. The 2011 diabetes guidelines of the 
Korean Diabetes Association (KDA) included using HbA1c 
≥ 6.5% for diagnosing diabetes [11].
To date, many studies support the use of glycosylated 
hemoglobin for diagnosing diabetes. The HbA1c level is 
a reliable indicator of chronic glycemia and correlates 
well with the risk of diabetes complications. Neverthe-
less, HbA1c is also affected by hemoglobinopathies, recent 
hemolysis, high triglyceride levels, pregnancy, and some 
drugs, including salicylates and vitamins C and E [12]. 
In addition, HbA1c does not reflect acute elevations in the 
glucose level [12]. Clinicians must be aware of these limita-
tions.
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